Verrica is advancing its lead product VP-102, a proprietary topical therapy, in many common skin indications including molluscum contagiosum (molluscum) and verruca vulgaris (common warts). Our lead product VP-102 is a topical that is applied directly to the lesions. VP-102 is designed to be convenient for both patients and practitioners. Verrica is also pursuing additional common dermal indications. We recently announced positive topline results from our Phase 3 CAMP-1 and CAMP-2 pivotal trials with VP-102 for the treatment of molluscum and our Phase 2 COVE-1 clinical study with VP-102 for the treatment of common warts.